Alt tag

aPROMISE

  • Prostatic lesions
  • Extraprostatic lesions
  • PET/CT

aPROMISE is intended to be used with PSMA images acquired using PET/CT imaging. The software provides a clinical application for oncology including detection and quantification of lesion candidates (in Bone, Lymph Node and Prostate).

Exini aPromise

Images shown for illustrative purposes only.

Circle

~29% and ~21% improved nodules detection

Riverain's AI suppression technology removes structures that can camouflage cancer and lung disease. 1,2

Circle

~26% and ~20% faster nodule search time

ClearRead CT technology helps radiologists see through the complexity to better detect abnormalities.1,2

Circle

Higher inter-reader agreement rates2

Clinical Workflow

clearread workflow

For CalanticTM software version 1.0.0 and older versions, no prior study will be examined.

white bg

 

    Scanning Parameters

    Appropriate Series for CT

    Photometric Interpretation (0028,0004) with value either MONOCHROME1 or MONOCHROME2

    Intensities in Hounsfield units

    Equally spaced slices, range 0.1 mm - 5.0 mm

    Equally spaced pixels, range 0.1 mm - 2.0 mm

     

    Appropriate Series for PET

    Photometric Interpretation (0028,0004) with value MONOCHROME2

    Equally spaced slices, range 1.4 mm - 5.0 mm

    Equally spaced pixels, range 1.4 mm - 5.5 mm

    Corrected Image (0028,0051) present with value ATTN or DECY

    Decay Correction (0054,1102) present with value START

    Units (0054,1001) present with value GML, CNTS, or BQML

    AI Output

    Picture Archiving and Communications System (PACS) tools, clinical application for oncology including marking of regions of interest and quantitative analysis.

    What Customers Are Saying

    The application enables identification of small nodules faster and more reliably, particularly for oncological patients.

    Terence Matalon, MD, Chairman of Einstein Medical Center Philadelphia’s Department of Radiology.

    May not reflect a typical user experience; actual results may vary.

    What Customers Are Saying

    ClearRead CT technology has helped us to detect lung nodules that may have otherwise been missed.

    Jared Christensen MD, MBA, Cardiothoracic Imaging at Duke University Medical Center.

    May not reflect a typical user experience; actual results may vary.

      Other Relevant Information

      Currently not made available with Calantic Viewer. Separately distributed by Bayer.

       

      EU risk class and CE marking
      aPROMISE has CE marking (CE0123) and risk class IIa.

      Reimbursement status
      Not reimbursed.

      Contraindications
      No contraindications given.

      Target population
      Not indicated.

      Intended User
      Trained healthcare professionals and researchers.

      Limitations

      - Always ensure that the patient name, patient ID and study date displayed in the patient section correspond to the patient case you intend to review.

      - The user must ensure the review of the image quality and quantification analysis results before signing the report.

      - Always review the images and quantification results in the report to ensure that the information saved and exported is correct.

      - The quantification analysis results provided by aPROMISE are intended to be used as complementary information together with other patient information and investigations used in the clinical decision making process. The user shall not rely solely on the information provided by aPROMISE for diagnostic or treatment decisions.

        References
        1.
        Instructions for Use aPROMISE, software version 1.4
        App gallery wave image
        Discover ClearRead CT

        Discover aPROMISE

        Now available as part of Calantic’s Prostate Service Line. Contact us today to learn more.

        Get a Demo

        Other Offerings in the Prostate Service Line

        Quantib
        Prostate

        Quantib Prostate

        • Intraprostatic lesions
        • MRI

        Learn More

        exini-app
        Prostate

        aBSI

        • Extraprostatic lesions
        • Bone Scintigraphy

        Learn More

        Alt tag

        © 2023 Bayer

        The descriptions, claims and visuals for all non-Bayer owned applications originate and are obtained from the application providers, or excerpted from publicly available information. Bayer is providing this content for your information, but does not own and control such content.

        BAYER, the Bayer Cross and Calantic are trademarks owned by Bayer and/or registered in the U.S. and/or other countries. Other trademarks and company names mentioned herein are properties of their respective owners.

        This is intended to provide information for healthcare professionals and other relevant decision makers in the European Union, United Kingdom and Switzerland. Not all offerings are available in all markets. For availability specific to your country please contact your local Bayer representative. These materials are exclusively for professional use.

         

        The product Calantic Viewer has CE marking (CE2797). Complies with medical device legislation. Consult the operating instructions of a product for its intended use, characteristics and performance, contraindications, name of the manufacturer or its authorized representative and other essential information. The operating instructions of the product Calantic Viewer can be found on https://www.radiology.bayer.com/manuals

         

        You are encouraged to report adverse events; reporting information can be found on https://www.bayer.com/en/pharma/report-side-effect

        Any individuals depicted in this website are actors and not actual health care providers or patients. All patient data is fictitious. Images are an artistic representation for illustrative purposes only.

         

        PP-CALA-ALL-0464-1 December 2023

         

        Bayer Logo